MedTrace Logo

To Investigate Pharmacokinetics and Pharmacodynamics of CJ-12420 After Single and Multiple Dose Administration

NCT03009760 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-01-20

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics and pharmacodynamics of CJ-12420 after single and multiple dose administration according to H. pylori infection.

Conditions

  • Healthy

Interventions

DRUG

CJ-12420 50mg(HP-)

CJ-12420 50mg in H. pylori negative subject

DRUG

CJ-12420 100mg(HP-)

CJ-12420 100mg in H. pylori negative subject

DRUG

CJ-12420 50mg(HP+)

CJ-12420 50mg in H. pylori positive subject

DRUG

CJ-12420 100mg(HP+)

CJ-12420 100mg in H. pylori positive subject

Sponsors & Collaborators

  • Asan Medical Center

    collaborator OTHER

  • HK inno.N Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-04-30
Completion
2016-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03009760 on ClinicalTrials.gov